309 completed, 33 unknown, 30 terminated, 18 withdrawn. 392 Phase 3, 45 Phase 2.
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder Glecaprevir/pibrentasvir, Placebo - PTSD | Phase 2 / Phase 3 | Unknown | White River Junction Veterans Affairs Medical Center | 92 | 2023-12-18 | 2025-04-24 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy. Zinc Supplement - Hepatitis C | Phase 3 | Completed | Tanta University | 50 | 2022-08-01 | 2023-10-17 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 286 | 2021-08-24 | 2025-04-06 |
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL, SOF/VEL/VOX - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 87 | 2020-01-03 | 2021-10-27 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis SOF/VEL - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 37 | 2019-10-16 | 2022-04-20 |
| HepATocellular Cancer Hcv Therapy Study Elbasvir / Grazoprevir Oral Tablet - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Withdrawn | Bayside Health | 2019-09-01 | 2020-09-14 | |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | Assiut University | 50 | 2019-09-01 | 2019-09-12 |
| A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients TG-2349, DAG181, Ribavirin - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 3 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 370 | 2019-06-13 | 2021-02-04 |
| Micro-elimination of Hepatitis C Virus Infection in Uremics Epclusa - Hepatitis C | Phase 3 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 135 | 2019-05-13 | 2020-07-10 |
| SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic | Phase 2 / Phase 3 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 440 | 2019-03-29 | 2019-08-28 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Safety of Sofosbuvir in People With Advanced Kidney Failure Sofosbuvir, Daclatasvir 60 mg - Kidney Failure, Chronic, Hepatitis C | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 30 | 2019-03-15 | 2021-04-06 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 3 | Unknown | Ginkgopharma CO., LTD | 206 | 2018-10-17 | 2019-06-28 |
| Transplantation Using Hepatitis C Positive Donors, A Safety Trial Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection | Phase 3 | Unknown | Jordan Feld | 40 | 2018-08-06 | 2019-07-12 |
| Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 Elbasvir, Grazoprevir 50-100Mg Oral Tablet - Hepatitis C, Chronic | Phase 3 | Completed | King Fahad Medical City | 30 | 2018-07-01 | 2020-11-20 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major | Phase 3 | Unknown | Ain Shams University | 24 | 2018-06-11 | 2023-03-06 |
Showing 20 of 392. Sign in to see all of them.
Hepatitis C, Chronic (201) · Fibrosis (30) · Hepatitis (18) · Liver Cirrhosis (17) · HIV Infections (15) · Liver Diseases (13) · Acquired Immunodeficiency Syndrome (11) · Virus Diseases (11) · Carcinoma, Hepatocellular (9) · Infections (7) · Hepatitis, Chronic (6) · Hepatitis, Viral, Human (6) · Bronchiolitis Obliterans Syndrome (5) · Digestive System Diseases (5)
Blood-Borne Infections (392) · Communicable Diseases (390) · Flaviviridae Infections (388) · Digestive System Diseases (387) · RNA Virus Infections (387) · Hepatitis, Viral, Human (386) · Infections (385) · Virus Diseases (381) · Liver Diseases (379) · Hepatitis (374) · Pathological Conditions, Signs and Symptoms (228) · Pathologic Processes (227) · Disease Attributes (207) · Chronic Disease (204) · Hepatitis, Chronic (196)
Ribavirin (195) · peginterferon alfa-2a (83) · peginterferon alfa-2b (53) · Sofosbuvir (49) · daclatasvir (32) · ombitasvir (32) · paritaprevir (30) · glecaprevir and pibrentasvir (28) · dasabuvir (27) · telaprevir (23) · glecaprevir (22) · pibrentasvir (21) · sofosbuvir-velpatasvir drug combination (20) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (18) · Simeprevir (17)
AbbVie (48) · Merck Sharp & Dohme LLC (43) · Gilead Sciences (40) · Bristol-Myers Squibb (26) · Boehringer Ingelheim (10) · Janssen R&D Ireland (9) · French National Agency for Research on AIDS and Viral Hepatitis (8) · Tanabe Pharma Corporation (8) · Hoffmann-La Roche (7) · AbbVie (prior sponsor, Abbott) (6) · Foundation for Liver Research (6) · Janssen-Cilag International NV (5) · Bausch Health Americas, Inc. (4) · Debiopharm International SA (4) · GlaxoSmithKline (4)
United States (116) · France (79) · Canada (74) · Germany (63) · Spain (61) · United Kingdom (57) · Puerto Rico (55) · Australia (50) · Italy (44) · Russia (39) · Belgium (38) · Poland (34) · Japan (31) · Egypt (28) · South Korea (26)
Ralph T. Doyle (4)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 28193518, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 36740893, PMID 20189674, PMID 22239511, PMID 22626609, PMID 23607593, PMID 23607594, PMID 24126097, PMID 25196718, PMID 25710287, PMID 25777337, PMID 26173631, PMID 26321288, PMID 26575258, PMID 26683763, PMID 26936417, PMID 27049487, PMID 27920566, PMID 28390869, PMID 28564569, PMID 29180522, PMID 29909549, PMID 30291369, PMID 32682494, PMID 37096802, PMID 16122679, PMID 16614742, PMID 16890601, PMID 17133492, PMID 17200799, PMID 17311621, PMID 17573387, PMID 17582705
2015 (22), 2014 (20), 2016 (8), 2004 (3), 2005 (3), 2008 (2), 2009 (2), 2017 (1), R01DA013759 (1), R01DA013763 (1), R01DA014499 (1), R01DA026727 (1), R21DA028645 (1), U01DK060309 (1), U01DK060324 (1)